Parnaparin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Parnaparin
Accession Number
DB09260
Type
Small Molecule
Groups
Approved, Investigational
Description

Parnaparin is an antithrombotic and belongs to the group of low molecular weight heparins.

Synonyms
  • Parnaparin sodium
Categories
UNII
M316WT19D8
CAS number
9005-49-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Parnaparin.Approved
AcenocoumarolParnaparin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Parnaparin.Approved, Vet Approved
AliskirenParnaparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Parnaparin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Parnaparin.Approved, Investigational
AlteplaseThe risk or severity of bleeding can be increased when Alteplase is combined with Parnaparin.Approved
AmikacinThe therapeutic efficacy of Amikacin can be decreased when used in combination with Parnaparin.Approved, Investigational, Vet Approved
AmilorideParnaparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Parnaparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Parnaparin.Approved
AncrodParnaparin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Parnaparin.Investigational
Antihemophilic factor, human recombinantThe therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Parnaparin.Approved, Investigational
Antithrombin III humanParnaparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanParnaparin may increase the anticoagulant activities of Apixaban.Approved
AprotininThe therapeutic efficacy of Parnaparin can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinParnaparin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanParnaparin may increase the anticoagulant activities of Argatroban.Approved, Investigational
AzelastineAzelastine may increase the anticoagulant activities of Parnaparin.Approved
Azilsartan medoxomilParnaparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Parnaparin.Approved, Investigational
BecaplerminParnaparin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeraprostBeraprost may increase the anticoagulant activities of Parnaparin.Investigational
BivalirudinBivalirudin may increase the anticoagulant activities of Parnaparin.Approved, Investigational
BuflomedilBuflomedil may increase the anticoagulant activities of Parnaparin.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Parnaparin.Investigational
CanagliflozinParnaparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanParnaparin may increase the hyperkalemic activities of Candesartan.Experimental
Candesartan cilexetilParnaparin may increase the hyperkalemic activities of Candesartan cilexetil.Approved
CangrelorCangrelor may increase the anticoagulant activities of Parnaparin.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Parnaparin.Experimental, Investigational
CarvedilolThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Carvedilol.Approved, Investigational
CertoparinParnaparin may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolCilostazol may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ClopidogrelClopidogrel may increase the anticoagulant activities of Parnaparin.Approved
CloricromenCloricromen may increase the anticoagulant activities of Parnaparin.Experimental
Coagulation factor VIIa Recombinant HumanThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Parnaparin.Approved
Collagenase clostridium histolyticumThe risk or severity of bleeding and hemorrhage can be increased when Parnaparin is combined with Collagenase clostridium histolyticum.Approved, Investigational
CyclosporineThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateParnaparin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinParnaparin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidParnaparin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DefibrotideDefibrotide may increase the anticoagulant activities of Parnaparin.Approved, Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Parnaparin.Investigational
DesirudinParnaparin may increase the anticoagulant activities of Desirudin.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Parnaparin.Approved, Investigational
DextranParnaparin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacThe risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Parnaparin.Approved, Vet Approved
DicoumarolParnaparin may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Parnaparin.Approved, Investigational
DipyridamoleDipyridamole may increase the anticoagulant activities of Parnaparin.Approved
Edetic AcidParnaparin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanParnaparin may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinParnaparin may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Parnaparin.Approved, Investigational
EplerenoneParnaparin may increase the hyperkalemic activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Parnaparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Parnaparin.Approved
EprosartanParnaparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideThe risk or severity of bleeding can be increased when Eptifibatide is combined with Parnaparin.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Parnaparin.Approved, Investigational, Vet Approved
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Parnaparin.Approved
Ethyl biscoumacetateParnaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidParnaparin may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanParnaparin may increase the hyperkalemic activities of Fimasartan.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Parnaparin.Approved, Vet Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Parnaparin.Approved, Investigational
FondaparinuxParnaparin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanParnaparin may increase the hyperkalemic activities of Forasartan.Experimental
FosinoprilThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Fosinopril.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Parnaparin.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Parnaparin.Experimental
HeparinParnaparin may increase the anticoagulant activities of Heparin.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Parnaparin.Investigational
IbudilastIbudilast may increase the anticoagulant activities of Parnaparin.Approved, Investigational
IbuprofenThe risk or severity of bleeding and hemorrhage can be increased when Ibuprofen is combined with Parnaparin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Parnaparin.Approved, Investigational, Nutraceutical
IdraparinuxParnaparin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Parnaparin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Parnaparin.Investigational
IloprostIloprost may increase the anticoagulant activities of Parnaparin.Approved, Investigational
IndobufenIndobufen may increase the anticoagulant activities of Parnaparin.Investigational
IrbesartanParnaparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
KetanserinKetanserin may increase the anticoagulant activities of Parnaparin.Investigational
KetorolacThe risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Parnaparin.Approved
LabetalolThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Labetalol.Approved
LetaxabanParnaparin may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelLevonorgestrel may decrease the anticoagulant activities of Parnaparin.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Parnaparin.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Parnaparin.Experimental
LosartanThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Losartan.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Parnaparin.Approved
Methyl salicylateThe risk or severity of bleeding can be increased when Methyl salicylate is combined with Parnaparin.Approved, Vet Approved
MetoprololThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Metoprolol.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Parnaparin.Approved
NadroparinParnaparin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NaftopidilThe risk or severity of bleeding can be increased when Naftopidil is combined with Parnaparin.Investigational
NaproxenThe risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Parnaparin.Approved, Vet Approved
NeomycinThe therapeutic efficacy of Neomycin can be decreased when used in combination with Parnaparin.Approved, Vet Approved
NimesulideThe risk or severity of bleeding and hemorrhage can be increased when Nimesulide is combined with Parnaparin.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Parnaparin.Investigational
OlmesartanParnaparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parnaparin.Approved
OtamixabanParnaparin may increase the anticoagulant activities of Otamixaban.Investigational
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Parnaparin.Approved
ParomomycinThe therapeutic efficacy of Paromomycin can be decreased when used in combination with Parnaparin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateParnaparin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateParnaparin may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Parnaparin.Approved, Investigational
PhenindioneParnaparin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonParnaparin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Parnaparin.Approved
PicotamidePicotamide may increase the anticoagulant activities of Parnaparin.Experimental
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Parnaparin.Approved, Withdrawn
PrasugrelPrasugrel may increase the anticoagulant activities of Parnaparin.Approved
PropafenoneThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Propafenone.Approved
PropranololThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Propranolol.Approved, Investigational
Protein CParnaparin may increase the anticoagulant activities of Protein C.Approved
ProtocatechualdehydeParnaparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Parnaparin.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Parnaparin.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Parnaparin.Approved, Experimental, Investigational
ReteplaseThe risk or severity of bleeding can be increased when Reteplase is combined with Parnaparin.Approved, Investigational
ReviparinParnaparin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Parnaparin.Approved
RivaroxabanParnaparin may increase the anticoagulant activities of Rivaroxaban.Approved
SacubitrilParnaparin may increase the hyperkalemic activities of Sacubitril.Approved
Salicylic acidThe risk or severity of bleeding can be increased when Salicylic acid is combined with Parnaparin.Approved, Investigational, Vet Approved
SaprisartanParnaparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinParnaparin may increase the hyperkalemic activities of Saralasin.Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Parnaparin.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Parnaparin.Approved, Vet Approved
Sodium CitrateSodium Citrate may increase the anticoagulant activities of Parnaparin.Approved, Investigational
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Parnaparin.Approved
SRT501SRT501 may increase the anticoagulant activities of Parnaparin.Investigational
SulfasalazineThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Parnaparin.Approved
SulindacThe risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Parnaparin.Approved, Investigational
SulodexideParnaparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TasosartanParnaparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanParnaparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TenecteplaseThe risk or severity of bleeding can be increased when Tenecteplase is combined with Parnaparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Parnaparin.Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Parnaparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Parnaparin.Approved
TirofibanTirofiban may increase the anticoagulant activities of Parnaparin.Approved
Tolfenamic AcidThe risk or severity of bleeding and hemorrhage can be increased when Tolfenamic Acid is combined with Parnaparin.Approved, Investigational
TranilastThe risk or severity of bleeding can be increased when Tranilast is combined with Parnaparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Parnaparin.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Parnaparin is combined with Treprostinil.Approved, Investigational
TriamtereneParnaparin may increase the hyperkalemic activities of Triamterene.Approved
TriflusalTriflusal may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Trolamine salicylateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Parnaparin.Approved
ValsartanParnaparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
VenlafaxineVenlafaxine may increase the antiplatelet activities of Parnaparin.Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Parnaparin.Approved
WarfarinParnaparin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranParnaparin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
  1. Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C: Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood. Thromb Haemost. 2007 Jun;97(6):965-73. [PubMed:17549299]
External Links
PubChem Substance
347910424
Wikipedia
Parnaparin
ATC Codes
B01AB07 — Parnaparin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentInfertilities / Low Molecular Weight Heparin1
3TerminatedTreatmentRetinal Vein Occlusions(RVO)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 26, 2015 11:08 / Updated on August 02, 2018 06:16